Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Antibody-Drug Conjugates (ADCs) represent an innovative class of potent anti-cancer
compounds that are widely used in the treatment of hematologic malignancies and solid …

Breast tumors generally consist of a diverse population of cells with varying gene expression
profiles. Breast tumor heterogeneity is a major factor contributing to drug resistance …

Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which,
via their antibody (mAb) component, deliver and release their potent warhead (aka. payload) …

A compound's intratumoural distribution is an important determinant for the effectiveness of
molecular therapy or imaging. Antibodies (Abs), though often used in the design of targeted …

The development of antibody-drug conjugates (ADCs) has significantly been advanced in
the past decade given the improvement of payloads, linkers and conjugation methods. In …

Poor tissue penetration remains a major challenge for antibody-based therapeutics of solid
tumors, but proper dosing can improve the tissue penetration and thus therapeutic efficacy of …

Antibody–drug conjugates (ADC) are a rapidly growing class of targeted cancer treatments,
but the field has experienced significant challenges from their complex design. This study …

Targeted delivery of chemotherapeutics aims to increase efficacy and lower toxicity by
concentrating drugs at the site-of-action, a method embodied by the seven current FDA …

Background: The non-homogenous distribution of antibody-drug conjugates (ADCs) within
solid tumors is a major limiting factor for their wide clinical application. Nanobodies have …